Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.38 USD | +0.27% | -8.31% | -24.41% |
May. 21 | The latest transactions by star managers | |
May. 16 | Fortrea Appoints Machelle Sanders to Board of Directors | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.41% | 2.36B | - | ||
+64.23% | 62.59B | B- | ||
-2.31% | 41.18B | B | ||
+45.55% | 40.29B | A | ||
-8.29% | 27.9B | C | ||
+11.97% | 26.21B | B- | ||
-21.16% | 19.09B | B | ||
+7.54% | 13.08B | B+ | ||
+27.17% | 12.05B | C+ | ||
+25.72% | 12.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FTRE Stock
- Ratings Fortrea Holdings Inc.